These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 22405267

  • 21. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW, NN9068-3912 (DUAL-II) Trial Investigators.
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E, Jonker DM, Jacobsen LV, Ingwersen SH.
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [Abstract] [Full Text] [Related]

  • 32. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M, Bouchard JR, Langer J.
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [Abstract] [Full Text] [Related]

  • 33. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S, Saxena GN, Keshwani P, Gupta R.
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 35. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Mateos JL, Wajchenberg BL.
    Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y, Rasmussen MF, Nishida T, Kaku K.
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [Abstract] [Full Text] [Related]

  • 37. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.
    J Med Econ; 2012 May; 15(4):746-57. PubMed ID: 22443463
    [Abstract] [Full Text] [Related]

  • 38. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [Abstract] [Full Text] [Related]

  • 39. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
    Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, Khunti K.
    Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
    [Abstract] [Full Text] [Related]

  • 40. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D, Cummins E, Royle P, Waugh N.
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.